Review

Misregulated RNA processing in amyotrophic lateral sclerosis

Magdalini Polymenidou\textsuperscript{a,c, 1}, Clotilde Lagier-Tourenne\textsuperscript{a,c, 1}, Kasey R. Hutt\textsuperscript{b,c, 1}, C. Frank Bennett\textsuperscript{d}, Don W. Cleveland\textsuperscript{a,c, *}, Gene W. Yeo\textsuperscript{b,c,**}

\textsuperscript{a}Ludwig Institute for Cancer Research, University of California at San Diego, La Jolla, CA 92093-6070, USA
\textsuperscript{b}Stem Cell Program and Institute for Genomic Medicine, University of California at San Diego, La Jolla, CA 92093-6070, USA
\textsuperscript{c}Department of Cellular and Molecular Medicine, University of California at San Diego, La Jolla, CA 92093-6070, USA
\textsuperscript{d}Isis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA

\textbf{ARTICLE INFO}

Article history:
Accepted 24 February 2012
Available online 3 March 2012

\textbf{Keywords:}
Amyotrophic lateral sclerosis
Frontotemporal dementia
TDP-43
FUS/TLS
C9orf72
RNA processing

\textbf{ABSTRACT}

Amyotrophic lateral sclerosis (ALS) research is undergoing an era of unprecedented discoveries with the identification of new genes as major genetic causes of this disease. These discoveries reinforce the genetic, clinical and pathological overlap between ALS and frontotemporal lobar degeneration (FTLD). Common causes of these diseases include mutations in the RNA/DNA-binding proteins, TDP-43 and FUS/TLS and most recently, hexanucleotide expansions in the C9orf72 gene, discoveries that highlight the overlapping pathogenic mechanisms that trigger ALS and FTLD. TDP-43 and FUS/TLS, both of which participate in several steps of RNA processing, are abnormally aggregated and mislocalized in ALS and FTLD, while the expansion in the C9orf72 pre-mRNA strongly suggests sequestration of one or more RNA binding proteins in pathologic RNA foci. Hence, ALS and FTLD converge in pathogenic pathways disrupting the regulation of RNA processing. This article is part of a Special Issue entitled RNA-Binding Proteins.

© 2012 Elsevier B.V. All rights reserved.

\textbf{Contents}

1. Introduction: ALS and FTLD are linked genetically, clinically and pathologically ........................................ 4
2. Misregulated RNA processing is a convergent causative basis for ALS and FTLD ...................................... 5
3. RNA processing alterations in ALS patients .................................................................................................. 5
4. Identification of TDP-43 RNA targets highlights its multifunctional role in RNA processing ...................... 6
5. TDP-43 regulation of its RNA targets converge in long synaptic transcripts and non-coding RNAs ........... 6
6. Autoregulatory mechanisms sustain the levels of TDP-43 protein ............................................................ 8
7. Perspectives and open questions ................................................................................................................. 8
Acknowledgments ........................................................................................................................................... 9
References ....................................................................................................................................................... 9

* Correspondence to: D.W. Cleveland, Ludwig Institute, Univ. of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0670, USA.
** Correspondence to: G.W. Yeo, Department of Cellular and Molecular Medicine, Univ. of California at San Diego, Sanford Consortium for Regenerative Medicine, 2880 Torrey Pines Scenic Drive, La Jolla, CA 92037, USA.
E-mail addresses: dceleveland@ucsd.edu (D.W. Cleveland), geneyeo@ucsd.edu (G.W. Yeo).

1 These authors contributed equally.

0006-8993/$ – see front matter © 2012 Elsevier B.V. All rights reserved.
1. Introduction: ALS and FTLD are linked genetically, clinically and pathologically

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that primarily targets motor neurons resulting in progressive paralysis and death within a few years from onset. Just like Alzheimer’s, Parkinson’s and other neurodegenerative diseases, a proportion (~10%) of ALS is dominantly inherited, while the remaining 90% (referred to as sporadic) do not have familial history. With the discovery of mutations in the gene encoding superoxide dismutase 1 (SOD1) as causative for 20% of inherited ALS (Rosen et al., 1993), and the generation of transgenic mice expressing ALS-causing SOD1 mutants (Bruijn et al., 1998; Gurney et al., 1994; Wong et al., 1995), the molecular era of deciphering disease mechanism was initiated. Indeed, most efforts to understand ALS pathogenesis over the last ~19 years have focused on disease caused by SOD1 mutations. Collectively, the work of multiple groups worldwide has established that mutant SOD1 synthesized within motor neurons and their glial neighbors provokes non-cell autonomous disease from one or more toxic properties of mutant SOD1 (reviewed in Boilée et al., 2006; Iliev et al., 2009; Pasinelli and Brown, 2006).

In 2006, a DNA/RNA-binding protein, called TAR DNA-binding protein (TDP-43) was found to be the major component of the cytoplasmic and ubiquitinated inclusions present in affected neurons of all sporadic ALS patients (Arai et al., 2006; Neumann et al., 2006) and in patients with frontotemporal lobar degeneration (FTLD), a neurodegenerative disorder characterized by behavioral and language disorders (Neary et al., 1998). This seminal discovery not only revolutionized the ALS field, but also significantly changed our perspective of neurodegeneration in general. Motor neuron disease and cognitive deficits of variable severity can be concomitant in patients or within families (Caselli et al., 1993; Lillo et al., 2012; Lomen-Hoerth et al., 2002; Neary et al., 2000; Ringholz et al., 2005) and the identification of a common pathological hallmark defined by TDP-43 and ubiquitin-positive, tau- and alpha-synuclein-negative cytoplasmic inclusions suggested that ALS and FTLD were part of a broad spectrum of neurodegeneration. In healthy neurons TDP-43 is localized mainly in the nucleus, raising the possibility that loss of nuclear localization in affected neurons is now reported in many neurodegenerative conditions besides ALS and FTLD, including a fraction of Alzheimer’s, Parkinson’s and Huntington’s disease patients (reviewed in Lagier-Tourenne et al.). These observations implicate the functional disruption of TDP-43 in the pathogenesis and/or progression of many, if not all, of these conditions.

Evidence supporting a primary causative role for TDP-43 in ALS and FTLD was reported in 2008 with the discovery of mutations within this gene in ALS patients (Gitcho et al., 2008; Kabashi et al., 2008; Sreedharan et al., 2008) and in rare FTLD patients (Benajiba et al., 2009; Borroni et al., 2009; Gitcho et al., 2009; Kovacs et al., 2009). Affected neurons of patients with TDP-43 mutations also present with cytoplasmic inclusions and nuclear loss (Van Deerlin et al., 2008), indicating that abnormal localization of TDP-43 represents the first mechanistic link between sporadic ALS and an inherited form caused by a known mutation.

The identification of TDP-43 as a major player in ALS and FTLD pathogenesis led to the discovery of ALS-causing mutations in a second gene, which encoded another DNA/RNA-binding protein called FUS/TLS for fused in sarcoma/translocated in liposarcoma (Kwiatkowski et al., 2009; Vance et al., 2009) in approximately 4% of familial ALS and in rare sporadic patients with no apparent familial history. Like TDP-43, FUS/TLS is mainly localized in the nuclei of unaffected neurons, but is partially cleared from those nuclei in neurons that contain cytoplasmic aggregations (Neumann et al., 2009; Tateishi et al., 2009; Vance et al., 2009). While most patients with FUS/TLS mutations develop a classical ALS phenotype without cognitive defect, occasionally, mutant FUS/TLS carriers develop either FTLD concurrently with motor neuron disease (Ticozzi et al., 2009) or FTLD in the absence of motor neuron deficits (Blair et al., 2009; Van Langenhove et al., 2010), providing further evidence that ALS and FTLD have clinical, pathological and genetic commonalities. Recent reports implicate TAF15 mutations in patients with ALS (Couthouis et al., 2011; Ticozzi et al., 2011). The fact that TAF-15 belongs to the same protein family as FUS/TLS (Bertolotti et al., 1999; Morohoshi et al., 1998), coupled with the observation that a fraction of RNA-binding proteins have exceptionally high aggregation propensities (Cushman et al., 2010), raise the likelihood that the list of misregulated RNA-binding proteins involved in ALS pathogenesis is still incomplete (Couthouis et al., 2011). TAF15 cytoplasmic accumulations were found in sporadic ALS patients (Couthouis et al., 2011), as well as patients with FTLD (Neumann et al., 2011), further supporting that the pathogenetic mechanisms of the two diseases are intertwined.

The strongest genetic link between ALS and FTLD was reported in late 2011 with the identification of hexanucleotide repeat expansions in the first intron of the C9orf72 gene as causative for ALS, FTLD or concomitant ALS-FTLD disease (DeJesus-Hernandez et al., 2011; Gijselinck et al., 2011; Renton et al., 2011). Today, expansions in the C9orf72 represent the most frequent genetic cause of ALS and patients carrying the mutation harbor characteristic pathologic hallmarks. In addition to TDP-43 pathology, patients with C9orf72 expansion display ubiquitin and p62 positive, TDP-43 negative cytoplasmic and intranuclear inclusions in various CNS regions including the cerebellum and hippocampus (Al-Sarraj et al., 2011; DeJesus-Hernandez et al., 2011; Murray et al., 2011; Troakes et al., 2011).

Not all ALS-causing genes, however, overlap with FTLD phenotypes. The recently discovered mutations in an X-linked gene, UBQLN2, encoding ubiquilin 2 is responsible for ~1% of familial ALS (Daoud and Rouleau, 2011; Deng et al., 2011). And while some patients carrying UBQLN2 mutations present with concomitant dementia, no reported UBQLN2-positive cases showed a pure FTLD phenotype in the absence
of motor system involvement (Deng et al., 2011; Millecamps et al., 2011b). Another recently identified ALS-causing gene is the OPTN gene encoding optineurin or optic neuropathy inducing protein, whose mutations were recently identified in Japanese familial ALS (Iida et al., 2011; Maruyama et al., 2010). OPTN mutations in Caucasian populations were reported to be either extremely rare (Del Bo et al., 2011; Sugihara et al., 2011; Tumer et al., 2012; van Blitterswijk et al., 2011) or completely absent (Millecamps et al., 2011a) and to date no association between OPTN mutations and FTLD phenotype has been found (Rollinson et al., 2012). The latter seems also to be true for SOD1, whose mutations seem to be strictly associated with ALS disease phenotype, in contrast to TDP-43, FUS/TLS and C9orf72.

2. Misregulated RNA processing is a convergent causative basis for ALS and FTLD

The mechanisms by which TDP-43 and FUS/TLS trigger neurodegeneration are at the earliest stages of investigation and it is at present unresolved as to whether neurodegeneration is due to a loss of function, a gain of toxic property, or a combination of the two arising from their sequestration into nuclear or cytoplasmic aggregates. If we consider the loss of function hypothesis, then the next question is: what are the physiological roles of TDP-43 and FUS/TLS whose interruption occurs in affected cells? While these are not fully elucidated and there is no evidence that TDP-43 and FUS/TLS act together, they are both structurally related to the family of heterogeneous ribonucleoproteins (hnRNPs) and have been involved in multiple levels of RNA processing including transcription, splicing, transport and translation. Such multifunctional proteins could have roles in coupling transcription with splicing and transport and translation. Such multifunctional proteins involved in ALS and other neurodegenerative disorders (Ilieva et al., 2009), may be triggered by TDP-43 or FUS/TLS inclusions. The observation that ALS-linked mutations increase the stability of TDP-43 protein (Guo et al., 2011; Johnson et al., 2009; Ling et al., 2010) supports the view that protein aggregation may initiate the pathogenic cascade in ALS. Moreover, TDP-43 and FUS/TLS are involved in the formation of stress granules, cytoplasmic foci containing RNA in complex with RNA binding proteins that appear transiently under cellular stress (Andersson et al., 2008; Bertolotti et al., 1999; Buratti and Baralle, 2008; Hirose and Manley, 2000; Kameoka et al., 2004; Law et al., 2006; Tan and Manley, 2009). It is therefore easy to imagine the devastating consequences of their functional disruption for cellular homeostasis.

The alternative hypothesis proposes that a gain of toxic property of TDP-43 and FUS/TLS cytoplasmic inclusions drives disease. Several of the neurotoxic mechanisms that have been proposed to result from the aggregates of different misfolded protein involved in ALS and other neurodegenerative disorders (Ilieva et al., 2009), may be triggered by TDP-43 or FUS/TLS inclusions. The observation that ALS-linked mutations increase the stability of TDP-43 protein (Guo et al., 2011; Johnson et al., 2009; Ling et al., 2010) supports the view that protein aggregation may initiate the pathogenic cascade in ALS. Moreover, TDP-43 and FUS/TLS are involved in the formation of stress granules, cytoplasmic foci containing RNA in complex with RNA binding proteins that appear transiently under cellular stress (Andersson et al., 2008; Bosco et al., 2011; Colombrita et al., 2009; Dewey et al., 2011; Gal et al., 2011; Ito et al., 2011; Liu-Yesucevitz et al., 2010; McDonald et al., 2011; Meyerowitz et al., 2011; Moisse et al., 2009; Wang et al., 2008a). Hence it is plausible that the physiologic TDP-43- or FUS/TLS-containing stress granules may transform into pathogenic inclusions during neurodegeneration. The observation that stress granule proteins partition in the TDP-43 and FUS/TLS pathologic inclusions of ALS patients supports this view (Dormann et al., 2011; Fujita et al., 2008; Liu-Yesucevitz et al., 2010). Therefore, sequestration of specific cellular RNAs within cytoplasmic TDP-43 and FUS/TLS inclusions may deplete the cell of essential RNA components, contributing to pathogenesis. The latter, if true, could explain the observation that TDP-43 and FUS/TLS binding to RNA is linked to their cytotoxicity independently of their propensity to aggregate (Elden et al., 2010; Sun et al., 2011; Voigt et al., 2010).

Just like TDP-43 and FUS/TLS, the pathogenic mechanism of the recently discovered hexanucleotide expansions in the C9orf72 gene is not understood, but there are two possible pathways emerging from early observations in these patients. The first one is a mechanism linked to haploinsufficiency of C9orf72 supported by the 50% reduction of C9orf72 transcript levels observed in patients with expansions (Dejesus-Hernandez et al., 2011; Gijselinck et al., 2011). As there is currently no functional or structural information on the C9orf72 protein, there is no evidence on the consequences of a C9orf72 haploinsufficiency. The second possibility is that the expanded RNA forms pathogenic foci (Dejesus-Hernandez et al., 2011) that trap one or more RNA binding protein(s). This mechanism of RNA toxicity resulting in the depletion and loss of function of specific RNA binding protein(s) with affinity for the expanded RNA has been established in other neurological diseases, especially myotonic dystrophy types 1 and 2 (Fugier et al., 2011; Kanadia et al., 2003; Mankodi et al., 2000, 2003; Margolis et al., 2006; Miller et al., 2000; Ranum and Cooper, 2006), or Fragile X-associated tremor ataxia syndrome (FXTAS) (Hagerman and Hagerman, 2004; Iwahashi et al., 2006; Jin et al., 2007; Sellier et al., 2011; Tassone et al., 2004; Willemsen et al., 2003). If a similar mechanism is demonstrated in ALS, it will further emphasize the crucial role of RNA misregulation in ALS pathogenesis. In addition, the role of RNA metabolism in ALS is further underscored by disease-causing mutations in angiogenin (Greenway et al., 2006; Li and Hu, 2011; Wu et al., 2007) and senataxin (Chen et al., 2004), two proteins involved in RNA processing, as well as by the recognition of intermediate length polyglutamine expansions in ataxin-2, another RNA binding protein, as a risk factor for ALS (Elden et al., 2010).

3. RNA processing alterations in ALS patients

Early studies have analyzed RNA expression profiles in affected postmortem tissues of sporadic ALS patients. While there is a large variation in the results reported, probably reflecting the heterogeneity in genetic background, disease stage and tissue preservation, neuroinflammatory pathways were uniformly seen activated in patients’ spinal cords (Malaspina et al., 2001) and motor cortices (Wang et al., 2006) and cell-death-associated genes are significantly upregulated in isolated motor neurons (Jiang et al., 2005). Importantly, splicing alterations were also reported in ALS patients (Lin et al., 1998; Rabin et al., 2010; Xiao et al., 2011), some of which may be directly related to TDP-43 misregulation (Xiao et al., 2011). Additionally, errors in adenosine (A) to inosine (I) RNA editing have been described in ALS patients (Kawahara et al., 2004), potentially resulting from loss of the RNA editing enzyme ADAR2.
(adenosine deaminase acting on RNA2) in neurons with TDP-43 cytoplasmic inclusions (Aizawa et al., 2010).

Altogether, the above observations reinforce the notion that abnormal RNA-processing contributes to ALS pathogenesis, albeit the role of TDP-43 or FUS/TLS in these modifications has not been accurately examined. It is now crucial to determine the normal functions of TDP-43 and FUS/TLS and to identify the set of alterations in RNA processing that define a TDP-43- and FUS/TLS-dependent disease signature.

4. Identification of TDP-43 RNA targets highlights its multifunctional role in RNA processing

Recent studies using revolutionary DNA sequencing technologies have provided initial insights on the normal functions of TDP-43 within the central nervous system. Until recently, only candidate approaches could be used to identify the RNA targets for specific RNA-binding proteins or aberrant RNA splice isoforms related to diseases. Advances in DNA sequencing technology have provided powerful tools for exploring gene regulation in remarkable detail. Indeed, using cross-linking, immunoprecipitation and high-throughput sequencing or CLIP-seq (Ule et al., 2003; Licatalosi et al., 2008; Yeo et al., 2009) or an alternative technique that omits the crosslinking step (RNA-immunoprecipitation or RIP-seq), TDP-43 RNA targets within the normal central nervous system were comprehensively defined (Polymenidou et al., 2011; Sephton et al., 2011; Tollervey et al., 2011). More than 6000 TDP-43 RNA targets have defined an RNA-protein interaction map, demonstrating a broad role of TDP-43 in RNA processing. While binding of TDP-43 on transcripts corresponding to approximately 30% of the mouse genome may seem like an overwhelming number, most RNA binding proteins, whose RNA targets have been previously comprehensively identified, show similar prolific binding patterns. For example, the RNA binding protein Nova was shown to bind 3754 genes in the targets have been previously comprehensively identified, a striking property of the most downregulated (~37 TDP-43 binding sites per pre-mRNA and 12 genes contained more than 100 binding sites).

Amidst the plethora of TDP-43 binding sites, it is crucial to determine the functional events that matter the most both physiologically and pathologically. To identify the contribution of TDP-43 in maintaining the levels and splicing patterns of RNAs, antisense oligonucleotide (ASO) silencing was used to deplete TDP-43 within the normal central nervous system of adult mice (Polymenidou et al., 2011). TDP-43 mRNA was degraded via endogenous RNase H digestion, which specifically recognizes ASO-pre-mRNA (DNA/RNA) hybrids. These tools enabled definition of RNA-processing alterations resulting from loss of function of TDP-43, using a genome-wide approach with high-throughput sequencing (known as RNA-seq) (Parkhomchuk et al., 2009). Following ASO-mediated depletion of TDP-43, levels of 601 mRNAs were changed and 965 splicing events were altered (Polymenidou et al., 2011).

In order to pinpoint changes in expression that resulted from direct interactions of TDP-43 protein with its target mRNAs, the RNA-binding sites for TDP-43 (obtained by CLIP-seq) were compared with the degree of expression change upon TDP-43 knockdown (RNA-seq). While very few TDP-43 binding sites were identified among genes whose mRNAs were upregulated after suppression of TDP-43, a striking enrichment of multiple binding sites was observed within the genes that were downregulated upon depletion of TDP-43 (Polymenidou et al., 2011). In fact, the 100 most downregulated genes upon TDP-43 reduction contained an average of ~37 TDP-43 binding sites per pre-mRNA and 12 genes contained more than 100 binding sites.

Another striking property of the most downregulated genes upon TDP-43 reduction was that they contained exceptionally long introns; on average, they were six-fold larger than the introns from unaffected or upregulated genes. Notably, pre-mRNAs with exceptionally long introns are most prominently represented in brain-enriched transcripts (Ameur et al., 2011; Polymenidou et al., 2011). Strikingly,
several of these RNAs encode proteins with crucial roles in synaptic activity/function and have previously been implicated in neurological diseases including Parkin (Park2), Neuroxin 1 and 3 (Nrxn1, Nrxn3) and Neurexin 1 (Nlgn1). Among this TDP-43 target group, Neuroxin 3 pre-mRNA was independently found downregulated in autopsy tissues from patients with TDP-43 pathology (Tollervey et al., 2011). It is important to emphasize that not all neuronal genes are affected by TDP-43 loss. For example, while Neurexin 1, a long-intron-containing gene is strongly affected, other members of the Neurexin family that contain substantially smaller introns (Neurexin 2 and 3) are neither significantly bound by TDP-43, nor altered in levels after TDP-43 depletion.

These results thus identify a novel conserved role for TDP-43 in regulating a subset of very long intron-containing brain-enriched genes and suggest for the first time a mechanism underlying the selective neuronal vulnerability from the interruption of TDP-43 function (Polymenidou et al., 2011). Nonetheless, the molecular events underlying this regulation have not been established. One possibility is that TDP-43 binding within long introns protects transcripts from undergoing nonsense-mediated mRNA decay by facilitating splicing events and preventing the introduction of premature termination codons. Indeed, TDP-43 may be involved in compacting the structure of RNA through multiple binding sites within long introns to facilitate their splicing. Another possibility is that TDP-43 affects RNA polymerase elongation, similar to what has been shown for another splicing regulator, SC35 (Lin et al., 2008). Future studies are needed to elucidate these mechanisms.

TDP-43 also interacts with and regulates the levels of long non-coding RNAs such as MALAT1 (Polymenidou et al., 2011; Tollervey et al., 2011) and NEAT1, which was markedly increased in expression in FTLD brains with TDP-43 pathology (Tollervey et al., 2011). The binding behavior of TDP-43 on small non-coding RNAs (sncRNAs) and mature micro-RNAs (miRNAs), however, remains unexplored. Nevertheless, association of TDP-43 with proteins involved in the miRNA biogenesis and maturation such as Drosha (Gregory et al., 2004), argonaute 2 and DDX17 (Freibaum et al., 2010; Ling et al., 2010) suggest that TDP-43 may participate in these pathways. Importantly, alterations in a set of miRNAs were reported in cultured cells following TDP-43 knockdown (Buratti et al., 2010). These include the miRNAs, let-7b and mir-663 expression, whose levels are down- and upregulated, respectively upon TDP-43 reduction and which were shown to bind TDP-43. Fig. 1 summarizes the main conclusions of the unbiased screens for TDP-43 binding sites in the nervous system.

It is noteworthy that while TDP-43 binds more than 6000 RNAs, only a small fraction of these change in splicing or expression when TDP-43 is depleted. So, what may be the purpose of TDP-43 binding on all these RNAs that seem to remain unaffected upon its loss? RNA binding may alter translation of some targets, as suggested for TDP-43 by a recent study (Fiesel et al., 2011), or facilitate the transport of others, as described above. Moreover, RNA-binding proteins often function in complexes and some redundancy may occur to ensure the most vital RNA-processing events. In agreement with this view, TDP-43 binding on UG elements in the vicinity of splice junctions was independently found to lack regulatory power in many instances (Passoni et al., 2011). Finally, given the reported role of TDP-43 in stress responses, one could speculate that in some instances, binding of TDP-43 to RNA is “inert” under physiological conditions and only becomes functional under cellular stress.

A largely unexplored aspect of TDP-43 (and FUS/TLS) biology is their role in transcription regulation through their DNA-binding properties. Indeed, TDP-43 was shown to bind TG-repeat-rich DNA, both single stranded (Acharya et al., 2006;
Buratti and Baralle, 2001) and double-stranded (Kuo et al., 2009). Originally identified as a transcriptional repressor that binds to transactive response (TAR) DNA of the human immunodeficiency virus type 1 (HIV-1) (Ou et al., 1995), TDP-43 was also reported to bind the promoter of the mouse SP-10 gene that is required for spermatogenesis (Abhyankar et al., 2007; Acharya et al., 2006; Laimansingh et al., 2011). In both instances, TDP-43 represses transcription by binding these DNA regulatory elements, but little is known about the mechanisms of this transcriptional repression (reviewed in Buratti and Baralle, 2008). While the above observations strongly suggest critical roles of TDP-43 in transcription regulation of a few gene targets, a comprehensive protein/DNA interaction map still remains to be defined.

Furthermore, it will be crucial to identify which of the TDP-43 regulated events are altered in ALS patients. Whole tissue transcriptome and/or splicing profiling may not accurately reveal the most relevant alterations but rather reflect modifications of the cellular composition in tissues with neuronal death and glial activation. While laser capture microdissection of motor neurons (Rabin et al., 2010) is a substantial technical improvement towards this goal, the reported heterogeneity of affected cells in the spinal cords of ALS patients (Bodansky et al., 2010; Giordana et al., 2009) may mask some of the changes occurring in the most severely affected neurons. Single cell transcriptome analysis (Tang et al., 2011) or pre-selection of cells that are at the same disease stage might shed light to this outstanding question. Another promising approach is the use of relatively homogeneous populations of neurons differentiated from induced pluripotent stem (iPS) cells generated from somatic cells isolated from ALS patients (Dimos et al., 2008; Han et al., 2011).

Similar high-throughput sequencing approaches to those followed for TDP-43 are underway to identify FUS/TLS RNA targets and RNA processing changes upon FUS/TLS depletion. Since the mutation or cytoplasmic aggregation of either FUS/TLS or TDP-43 cause similar disease phenotypes in humans, the autoregulatory mechanisms that have evolved to maintain its levels (Ayala et al., 2011; Polymenidou et al., 2011; Sephton et al., 2011). Binding of TDP-43 causes the removal of this intron, evidenced by the dramatic increase of this 3’UTR-spliced TDP-43 isoform, upon overexpression of TDP-43 in cultured cells (Polymenidou et al., 2011). Locations of introns are demarcated by the presence of exon-junction complexes (EJCs) deposited on the mature mRNA proximal to the exon-exon junction. The pioneer round of translation normally ejects EJCs upstream of the stop codon, the presence of an unperturbed EJC elicits the nonsense mediated decay (NMD) pathway which causes degradation of the TDP-43 message (Ayala et al., 2011; Polymenidou et al., 2011). Interestingly, many other RNA binding proteins are auto-regulated via the NMD pathway (Dredge et al., 2005; Lareau et al., 2007; Ni et al., 2007; Saltzman et al., 2008; Sureau et al., 2001; Wollerton et al., 2004). The NMD pathway, however, is not the only possible autoregulatory mechanism shown for TDP-43 (Lee et al., 2012). Other mechanistic contributors to TDP-43 autoregulation include the promotion by TDP-43 overexpression in cultured cells of RNA-instability in an exosome-dependent fashion, suggesting a complementary pathway for sustaining its levels (Ayala et al., 2011). Additional mechanisms, such as miRNA-mediated regulation may also contribute to the maintenance of TDP-43 levels. Indeed, conserved binding sites for the miRNA miR-143 were identified in TDP-43 molecules of multiple vertebrates (Trakooljul et al., 2009). In the future, it will be important to clarify the level of contribution of each pathway to the autoregulation of TDP-43 in the mouse and human nervous system.

Whatever the underlying molecular mechanism(s), the tight autoregulation of TDP-43 provides an attractive model for a feed-forward mechanism driving disease progression in ALS patients. In cells with cytoplasmic accumulations of TDP-43 and consequent nuclear clearance of the protein, the production of stable TDP-43 mRNA will be expected to increase, which may further promote the growth of the cytoplasmic aggregates, as more and more TDP-43 protein gets incorporated into the growing aggregates (Fig. 2). The observed increased levels of TDP-43 mRNA in motor neurons from ALS patients (Rabin et al., 2010) supports this view.

6. Autoregulatory mechanisms sustain the levels of TDP-43 protein

The multifunctional role and physiological importance of TDP-43 is evidenced by early embryonic lethality in mice with homozygous disruption in the Tardbp gene (Kraemer et al., 2010; Sephton et al., 2010; Wu et al., 2010) and by autoregulatory mechanisms that have evolved to maintain its levels (Ayala et al., 2011; Igaz et al., 2011; Polymenidou et al., 2011; Xu et al., 2010) to avoid toxicity caused by elevated TDP-43 expression (Shan et al., 2010; Tsai et al., 2010; Wils et al., 2010; Xu et al., 2010). In fact, TDP-43 was found highly expressed in the developing nervous system, with lower levels in adult rodents that are sustained with age (Huang et al., 2010), confirming the vital role of this protein for the homeostasis of the adult nervous system.

Evidence for tight regulation of TDP-43 levels came from cellular and animal models where over-expression of exogenous TDP-43 induced striking reduction of endogenous TDP-43 RNA and protein levels (Ayala et al., 2011; Igaz et al., 2011; Polymenidou et al., 2011; Xu et al., 2010). The genome-wide identification of TDP-43 binding sites revealed that TDP-43 protein binds within an intron residing in the 3’UTR of its own pre-mRNA (Ayala et al., 2011; Polymenidou et al., 2011; Sephton et al., 2011). The genome-wide identification of TDP-43 binding sites revealed that TDP-43 protein binds within an intron residing in the 3’UTR of its own pre-mRNA (Ayala et al., 2011; Polymenidou et al., 2011; Sephton et al., 2011). Binding of TDP-43 causes the removal of this intron, evidenced by the dramatic increase of this 3’UTR-spliced TDP-43 isoform, upon overexpression of TDP-43 in cultured cells (Polymenidou et al., 2011). Locations of introns are demarcated by the presence of exon-junction complexes (EJCs) deposited on the mature mRNA proximal to the exon-exon junction. The pioneer round of translation normally ejects EJCs upstream of the stop codon, the presence of an unperturbed EJC elicits the nonsense mediated decay (NMD) pathway which causes degradation of the TDP-43 message (Ayala et al., 2011; Polymenidou et al., 2011). Interestingly, many other RNA binding proteins are auto-regulated via the NMD pathway (Dredge et al., 2005; Lareau et al., 2007; Ni et al., 2007; Saltzman et al., 2008; Sureau et al., 2001; Wollerton et al., 2004). The NMD pathway, however, is not the only possible autoregulatory mechanism shown for TDP-43 (Lee et al., 2012). Other mechanistic contributors to TDP-43 autoregulation include the promotion by TDP-43 overexpression in cultured cells of RNA-instability in an exosome-dependent fashion, suggesting a complementary pathway for sustaining its levels (Ayala et al., 2011). Additional mechanisms, such as miRNA-mediated regulation may also contribute to the maintenance of TDP-43 levels. Indeed, conserved binding sites for the miRNA miR-143 were identified in TDP-43 molecules of multiple vertebrates (Trakooljul et al., 2009). In the future, it will be important to clarify the level of contribution of each pathway to the autoregulation of TDP-43 in the mouse and human nervous system.

Whatever the underlying molecular mechanism(s), the tight autoregulation of TDP-43 provides an attractive model for a feed-forward mechanism driving disease progression in ALS patients. In cells with cytoplasmic accumulations of TDP-43 and consequent nuclear clearance of the protein, the production of stable TDP-43 mRNA will be expected to increase, which may further promote the growth of the cytoplasmic aggregates, as more and more TDP-43 protein gets incorporated into the growing aggregates (Fig. 2). The observed increased levels of TDP-43 mRNA in motor neurons from ALS patients (Rabin et al., 2010) supports this view.

7. Perspectives and open questions

While we are witnessing a time of remarkable progress in our understanding of the complex roles of TDP-43, FUS/TLS and other RNA binding proteins in the homeostasis and degeneration of the nervous system, there is undeniably a long list of key, outstanding questions that must be addressed in the near future. Included here are what are the FUS/TLS-dependent RNA-processing events and what is the overlap between...
the TDP-43 and FUS/TLS regulated events? Which, if any, are the RNA binding proteins trapped in the RNA-foci of patients with C9orf72 expansions and what are the downstream mis-regulated RNA-processing events? Pertinently, is there convergence of the three seemingly distinct pathways driving disease, i.e. TDP-43, FUS/TLS and C9orf72 expansions? Are familial ALS cases caused by SOD1, optineurin or ubiquilin 2 mutations triggered by similar mechanisms, or do multiple pathogenic mechanisms lead to the same disease phenotype? Are there more repeat expansions causing ALS and FTLD? Why are TDP-43 and FUS so commonly aggregated in neurodegeneration? Is this due to their normal roles in the cellular stress response pathway? What defines the disease phenotype in ALS and FTLD? Is there truly sporadic disease, and what causes it? Or are there multiple genetic and/or environmental factors triggering sporadic ALS?

As long and challenging as the above list may seem, the next few years of ALS and FTLD research will be even more exciting than the past has been and new discoveries will empower therapeutic interventions for these devastating conditions.

Acknowledgments

M.P. was the recipient of a long-term fellowship from the international Human Frontier Science Program Organization. C.L.-T was the recipient of a long-term fellowship from the international Human Frontier Science Program Organization. C.L.-T. was the recipient of the Milton-Safenowitz post-doctoral fellowship from the Amyotrophic Lateral Sclerosis Association and is supported by a development grant from the Muscular Dystrophy Association. The authors receive support from the National Institute of Neurological Disorders and Stroke, K99NS075216 to M.P. and R37NS27036 to D.W.C, as well as from the National Institutes of Health (HG004659 and GM084317 to G.W.Y), the California Institute for Regenerative Medicine (RB1-01413 to G.W.Y) and the Stem Cell Program at the University of California, San Diego (G.W.Y). G.W.Y. is an Alfred P. Sloan Research Fellow (2011–2012).

REFERENCES


positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS. Acta Neuropathol. 122, 691–702.


